(per TU zoo mab)
- 2C4 Antibody
- MOAB 2C4
- Monoclonal Antibody 2C4
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous [preservative free]:
Perjeta: 420 mg/14 mL (14 mL) [contains mouse (murine) and/or hamster protein]
Brand Names: U.S.
- Antineoplastic Agent, Anti-HER2
- Antineoplastic Agent, Monoclonal Antibody
Pertuzumab is a recombinant humanized monoclonal antibody which targets the extracellular human epidermal growth factor receptor 2 protein (HER2) dimerization domain. Inhibits HER2 dimerization and blocks HER downstream signaling halting cell growth and initiating apoptosis. Pertuzumab binds to a different HER2 epitope than trastuzumab so that when pertuzumab is combined with trastuzumab, a more complete inhibition of HER2 signaling occurs (Baselga, 2012).
Vd: 5.12 L (Gianni, 2010)
Terminal: 18 days
Use: Labeled Indications
Breast cancer, metastatic: Treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (in combination with trastuzumab and docetaxel) in patients who have not received prior anti-HER2 therapy or chemotherapy to treat metastatic disease.
Breast cancer, neoadjuvant treatment: Neoadjuvant treatment of locally advanced, inflammatory, or early stage HER2-positive, breast cancer (either greater than 2 cm in diameter or node positive) in combination with trastuzumab and docetaxel (as part of a complete treatment regimen for early breast cancer).
Limitations of use: The safety of pertuzumab as part of a doxorubicin-containing regimen has not been established; the safety of pertuzumab administered for more than 6 cycles for early breast cancer has not been established.
Known hypersensitivity to pertuzumab or any component of the formulation
Note: For pertuzumab, trastuzumab, and docetaxel combination regimens, pertuzumab and trastuzumab may be administered in any order; however, docetaxel should be given after pertuzumab and trastuzumab. Observe patients for 30 to 60 minutes after each pertuzumab infusion and before subsequent infusions of trastuzumab or docetaxel.
Breast cancer, metastatic HER2+: IV: 840 mg over 60 minutes followed by a maintenance dose of 420 mg over 30 to 60 minutes every 3 weeks until disease progression or unacceptable toxicity (in combination with trastuzumab and docetaxel) (Baselga, 2012; Swain, 2015).
Breast cancer, neoadjuvant treatment HER2+: Adults: IV: 840 mg over 60 minutes followed by a maintenance dose of 420 mg over 30 to 60 minutes every 3 weeks for 3 to 6 cycles; may be administered as one of the regimens below. Postoperatively, continue trastuzumab to complete 1 year of treatment.
Four preoperative cycles of pertuzumab, trastuzumab, and docetaxel, followed by 3 postoperative cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) (Gianni, 2012) or
Three preoperative cycles of FEC (alone) followed by 3 preoperative cycles of pertuzumab, trastuzumab, and docetaxel (Schneeweiss, 2013) or
Six preoperative cycles of pertuzumab, trastuzumab, docetaxel, and carboplatin (Schneeweiss, 2013)
Missed doses or delays: If <6 weeks has elapsed, administer the 420 mg maintenance dose; do not wait until the next planned dose. If ≥6 weeks has elapsed, readminister the 840 mg initial dose (over 60 minutes), and then follow with a maintenance dose of 420 mg (over 30 to 60 minutes) every 3 weeks.
Refer to adult dosing.
Dosing: Renal Impairment
CrCl ≥30 mL/minute: No dosage adjustment necessary.
CrCl <30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).
Dosing: Adjustment for Toxicity
Note: Dose reductions are not recommended for pertuzumab; if trastuzumab is withheld, pertuzumab should also be withheld; if trastuzumab is discontinued, pertuzumab should be discontinued; pertuzumab and trastuzumab may be continued if docetaxel is discontinued.
Infusion-related reaction: Slow or interrupt the infusion
Serious hypersensitivity: Discontinue immediately
Cardiotoxicity: Left ventricular ejection fraction (LVEF) declines to <45% or LVEF 45% to 49% with ≥10% absolute decrease below pretreatment values: Withhold treatment (pertuzumab and trastuzumab) for at least 3 weeks; may resume if LVEF returns to >49% or to 45% to 49% with <10% absolute decrease below pretreatment values. If after a repeat assessment within ~3 weeks, LVEF has not improved (or has declined further), discontinue pertuzumab and trastuzumab (unless the benefit of treatment outweighs risks).
Dilute in 250 mL NS only (do not use dextrose 5% solutions) in PVC or non-PVC (polyolefin) bags. Gently invert to mix (avoid foaming); do not shake. Do not mix with other medications.
For IV infusion only, as a short infusion; infuse initial dose (840 mg) over 60 minutes; infuse maintenance dose (420 mg) over 30 to 60 minutes. Do not administer IV push or as a rapid bolus. Do not mix with other medications. For pertuzumab, trastuzumab, and docetaxel combination regimens, pertuzumab and trastuzumab may be administered in any order; however, docetaxel should be given after pertuzumab and trastuzumab. Observe patients for 30 to 60 minutes after each pertuzumab infusion and before subsequent infusions of trastuzumab or docetaxel.
Store intact vials at 2°C to 8°C (36°F to 46°F) until time of use. Protect from light. Do not freeze. Do not shake. Solutions diluted for infusion in NS should be used immediately; if not used immediately, maybe stored at 2°C to 8°C (36°F to 46°F) for up to 24 hours.
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. Avoid combination
Note: Reactions reported in combination therapy with trastuzumab and docetaxel unless otherwise noted.
Central nervous system: Fatigue (26% to 38%), headache (11% to 21%), decreased left ventricular ejection fraction (8% to 16%), insomnia (8% to 13%), dizziness (3% to 13%)
Dermatologic: Alopecia (52% to 65%), skin rash (11% to 34%; grades 3/4: <1%), pruritus (4% to 14%), palmar-plantar erythrodysesthesia (11%), xeroderma (9% to 11%)
Gastrointestinal: Diarrhea (46% to 67%; grades 3/4: 5% to 8%), nausea (39% to 53%; monotherapy 24%), vomiting (13% to 36%; monotherapy 15%), decreased appetite (11% to 29%), constipation (23%), mucositis (20% to 28%), stomatitis (17% to 19%), dysgeusia (13% to 18%), abdominal pain (monotherapy 12%)
Hematologic & oncologic: Neutropenia (47% to 53%; grades 3/4: 43% to 49%), anemia (3% to 23%; grades 3/4: 3% to 4%), leukopenia (9% to 16%; grades 3/4: 5% to 12%), febrile neutropenia (8% to 14%; grades 3/4: 9% to 13%)
Hypersensitivity: Hypersensitivity (1% to 11%; grades 3/4: 2%)
Neuromuscular & skeletal: Weakness (15% to 26%), myalgia (11% to 23%), arthralgia (10% to 12%)
Respiratory: Upper respiratory tract infection (4% to 17%; grades 3/4: <1%), epistaxis (11%)
Miscellaneous: Fever (9% to 19%; grades 3/4: 1%), infusion reactions (13%; grades 3/4: <1%)
1% to 10%:
Cardiovascular: Left ventricular dysfunction (3% to 4%), peripheral edema (3% to 4%)
Central nervous system: Peripheral sensory neuropathy (8%; grades 3/4: 1%), peripheral neuropathy (1%)
Dermatologic: Nail disease (7%), paronychia (1% to 7%)
Gastrointestinal: Dyspepsia (8%), anorexia (monotherapy 5%)
Hematologic & oncologic: Thrombocytopenia (1%)
Hepatic: Increased serum ALT (3%)
Ophthalmic: Increased lacrimation (4% to 5%)
Respiratory: Dyspnea (5% to 8%), nasopharyngitis (7%), oropharyngeal pain (7%), cough (5%)
<1%, postmarketing, and/or case reports with combination therapy: Heart failure, pleural effusion, sepsis
Concerns related to adverse effects:
• Cardiotoxicity: [US Boxed Warning]: May result in cardiac failure (clinical and subclinical) manifesting as decreased left ventricular ejection fraction (LVEF) and heart failure (HF). Assess cardiac function at baseline and during treatment. Discontinue for confirmed clinically significant decline in left ventricular function. Decreases in LVEF are associated with HER2 inhibitors, including pertuzumab. Patients who received prior anthracycline therapy or chest irradiation may be at an increased risk for cardiotoxicity. In studies of pertuzumab (versus placebo) in combination with trastuzumab and docetaxel for the treatment of metastatic breast cancer, the rate of cardiotoxicity (LVEF decline or symptomatic LV systolic dysfunction) was not increased in the pertuzumab group when compared to placebo. In the neoadjuvant setting, the incidence of LV dysfunction was higher in patients treated with pertuzumab. In a study of pertuzumab, trastuzumab, and docetaxel, compared with trastuzumab and docetaxel, the incidence of LVEF decline (of >10% decrease from baseline or to <50%) was 8.4% and 1.9%, respectively; LVEF recovered to ≥50% in all patients. In another neoadjuvant study, LVEF declines (of >10% decrease from baseline or to <50%) were noted in 6.9% to 16% of patients receiving various combinations and sequences of pertuzumab plus trastuzumab with FEC (fluorouracil, epirubicin, and cyclophosphamide), docetaxel, and/or carboplatin; LVEF recovered to ≥50% in most patients. Of note, patients with pretreatment LVEF ≤50%, CHF, LVEF decreases to <50% during prior trastuzumab treatment, or conditions which could impair LV function (eg, uncontrolled hypertension, recent MI, serious arrhythmia requiring treatment, or cumulative lifetime anthracycline exposure >360 mg/m2 doxorubicin or its equivalent) were excluded from studies. Assess LVEF at baseline, every 3 months during treatment (metastatic patients) or every 6 weeks during treatment (neoadjuvant setting), and every 6 months after therapy discontinuation up to 24 months after the last dose of pertuzumab and/or trastuzumab. Withhold pertuzumab and trastuzumab if LVEF <45% or 45% to 49% with a ≥10% absolute decline from baseline; repeat LVEF assessment in ~3 weeks; discontinue if LVEF has not improved or has declined further (unless potential benefits outweigh risks).
• Gastrointestinal adverse events: Diarrhea occurred more frequently in patients receiving pertuzumab in combination with trastuzumab and docetaxel, compared to patients receiving only trastuzumab and docetaxel.
• Hypersensitivity/infusion reaction: Infusion reactions (either during or on the day of infusion) have been associated with pertuzumab; commonly described as fever, chills, fatigue, headache, weakness, myalgia, hypersensitivity, abnormal taste or vomiting. The incidence of hypersensitivity/anaphylaxis was slightly higher in the group receiving pertuzumab (compared to placebo) in combination with trastuzumab and docetaxel. Monitor for 1 hour after the first infusion and for 30 minutes after subsequent infusions. For significant infusion reactions, interrupt or slow infusion rate; for severe infusion reactions, consider permanently discontinuing. Medications and equipment for the treatment of hypersensitivity should be available for immediate use during infusion.
Concomitant drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Pregnancy: [US Boxed Warning]: Pertuzumab exposure during pregnancy may result in embryo-fetal mortality and birth defects. Advise patients of the risks and the need for effective contraception. Verify pregnancy status prior to treatment initiation. Effective contraception should be used by all patients receiving pertuzumab during therapy and for 7 months after the last dose (of pertuzumab in combination with trastuzumab) for women of childbearing potential.
• HER2 expression: Establish HER2 status prior to treatment; has only been studied in patients with evidence of HER2 overexpression, either as 3+ IHC (Dako Herceptest) or FISH amplification ratio ≥2 (Dako HER2 FISH pharmDx test).
•Limitations of use: Safety of combination or sequential therapy with doxorubicin-containing regimens has not been established. For early breast cancer, the safety of treatment beyond 6 cycles has not been determined.
HER2 expression (either as 3+ IHC [Dako Herceptest™] or FISH amplification ratio ≥2 [Dako HER2 FISH pharmDx™ test]); pregnancy test; assess LVEF at baseline, every 3 months during treatment (more frequently for declines) in metastatic treatment and every 6 weeks for neoadjuvant treatment, and every 6 months following discontinuation for up to 24 months from the last dose of pertuzumab and/or trastuzumab); monitor for infusion reaction and hypersensitivity
[US Boxed Warning]: Pertuzumab exposure during pregnancy may result in embryo-fetal mortality and birth defects. Advise patients of the risks and the need for effective contraception. Verify pregnancy status prior to treatment initiation (in women of reproductive potential). Based on the mechanism of action of pertuzumab and data from similar agents, oligohydramnios or oligohydramnios sequence may occur resulting in pulmonary hypoplasia, skeletal anomalies, and neonatal death. Monitor for oligohydramnios if exposure occurs during pregnancy or within 7 months prior to conception; conduct appropriate fetal testing if oligohydramnios occurs. Effective contraception should be used during therapy and for 7 months after the last dose (of pertuzumab in combination with trastuzumab) for women of childbearing potential. Advise patients to immediately report to healthcare provider if pregnancy is suspected during treatment. If pertuzumab exposure occurs during pregnancy or exposure to pertuzumab in combination with trastuzumab occurs within 7 months prior to conception, healthcare providers should report the exposure to the Genentech Adverse Event Line (888-835-2555).
Women exposed to pertuzumab during pregnancy or exposed to pertuzumab in combination with trastuzumab within 7 months prior to conception are encouraged to enroll in MotHER Pregnancy Registry (1-800-690-6720 or www.motherpregnancyregistry.com).
European Society for Medical Oncology (ESMO) guidelines for cancer during pregnancy recommend delaying treatment with HER2-targeted agents until after delivery in pregnant patients with HER2-positive disease (Peccatori 2013).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience dizziness, abdominal pain, mouth sores, lack of appetite, bad taste, itching, or dry skin. Have patient report immediately to prescriber signs of heart problems (cough or shortness of breath that is new or worse, swelling of the ankles or legs, abnormal heartbeat, weight gain of more than five pounds in 24 hours, dizziness, or passing out), signs of infection, angina, tachycardia, severe headache, severe nausea, vomiting, severe diarrhea, bruising, bleeding, loss of strength and energy, or burning or numbness feeling (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.